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Risk of Primary and Recurrent 
Acute Myocardial Infarction 
From Lipoprotein(a)-I 
Numerous studies in newborns, infants, children, adults, parents 
and grandparents have conclusively demonstrated that serum levels 
of lipoprotein(a) [Lp(a)] are largely genetically determined, with 
full expression of the Lp(a) gene in the first year of life. Serum 
levels of Lp(a) increase twofold between the first week and 8.5 
months of age to reach stable, life-long levels (1). Lp(a) levels at 8.5 
months of .. ge are not different from parental values and are closely 
correlated with that of the affected parent (1). Lp(a) levels in 
children 8 to 12 years old are highly correlated with premature 
coronary artery disease (CAD) and "coronary history score" in 
grandparents (2). Parents of male children with Lp(a) levels >25 
mg/dl have a 2.5-fold higher incidence of mpcardial infarction 
(MI) (3). I therefore disagree with the conclusion of Kinley et al. (4) 
from the Australian Monitoring Trends and Determinants in Car-
diovascular Disease (MONICA) study that elevated serum levels of 
Lp(a) may be the effect of advanced atherosclerosis and MI rather 
than the cause. The results from two other MONICA centers 
appear to provide insights into the paradoxically higher Lp(a) levels 
in patients without than with recurrent MI. In the Scottish 
MONICA study (5), compared with age-matched men, the fatality 
rates for MI in women were 14% higher after admission to the 
hospital and 22% higher after admission to coronary care, yet the case 
fatality rates at 28 days were identical (men 49.8%; women 49.6%). 
Women had more shock and syncope and had a worse prognosis in the 
hospital only because an equivalent number of men had died suddenly 
before reaching the hospital. Prehospital death accounted for 74% of 
deaths in men compared with only 65% in women (5). The New 
Zealand MONICA study (6) also had similar results, with identical 
28-day case fatality rates in both men and women. The higher case 
fatality rate after hospital admission was compensated by a lower 
prehospital CAD case fatality in women. A higher rate of death after 
MI in patients with high levels of Lp(a) is highly plausible, as discussed 
later. 
In a study (7) of 79 Swedish men who survived an MI before the 
age of 45, reinfarction occurred within 3 years in 16 and was fatal in 
9 (56%). Lp(a) levels were highly correlated with the coronary 
stenosis score as well as the recurrence of MI. Mean Lp(a) levels 
were twofold higher in patients without and fourfold higher in those 
with recurrent MI than in the control population. In a British study 
of 266 patients followed up for 965 days after an acute MI, elevated 
levels of Lp(a) were' an independent risk factor for cardiac mortal-
ity, with a relative risk of 2.16 on multivariant analysis (8). Those 
patients wi~h Lp(a) levels >30 mg/dl had s. significantly higher 
cardiac nvrtality rate (29.8% vs. 18.6%, P == 0.05) than those with 
Lp(a) levds <30 mg/dl. 
Patif;nts with higher levels of Lp(a) in the present study (4) 
indeed had advanced coronary atherosclerosis disease, a powerful 
prognostic factor for cardiac morbidity and mortality, including out 
of hcapital deaths (9). Others (10,11) have also reported significant 
corn~lation of Lp(a) levels with the extent, severity and rapid 
angiographic progression of CAD (12), 111 of which are highly 
predictive of the development of clinical coronary events and 
mortality after an MI (13). Thus, the exclusion of patients who died 
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outside the hospital in the study by Kinley et al. (4) may have biased 
their results and conclusions. 
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Risk of Primary and Recurrent 
Acute Myocardial Infarction 
From Lipoprotein(a)-II 
Kinlay et al. (1) have shown, as have others, that a high lipoprotein(a) 
[Lp( a)] concentration is a significant but weak predictor of myocardial 
infarction risk. In contrast, in a recent prospective cross-sectional study 
Table 1. Independent Predictors (p < 0.01) of Coronary Artery 
Disease Score in White or Indo-Asian Patients Ranked in Order of 
Explanatory Value (contribution to cumulative adjusted r2)* 
Metabolic Variable 
White patients (n = 102) 
Lp(a) 
Fasting insulin 
Total cholesterol 
Triglycerides 
Indo-Asian patients (n = 102) 
Lp(a) 
Total cholesterol 
Fasting insulin 
HOL cholesterol 
Cumulative r Value 
0.24 
0.38 
0.45 
0.50 
0.21 
0.35 
0.41 
0.45 
*Oata from Shaukat et a!. (2). HOL = high density lipoprotein; Lp(a) = 
lipoprotcln(a). 
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(2), we found Lp(a) concentrations to be by far the best predictor of 
the extellt of coronal)' disease, as measured by an angiographic stenosis 
score (Table 1) in both white and Indo-Asian patients. Again, this 
finding accords with previous reports. Are the data really so contra-
dict '.)l)'? 
As we pointed out some years ago (3), although the individual risk 
of myocardial infarction correlates with coronal)' disease burden, on a 
population basis, the commonest angiographic finding in whites pre-
senting <70 years old with a first myocardial infarction is single-vessel 
disease. It is therefore not surprising that Lp(a) concentration is a 
mediocre predictor of myocardial infarction risk in Australian whites, 
although as Kinlay et al. acknowledge, a different pattern may emerge 
in blacks or Indo-Asians, who are more likely to have multivessel 
disease at the time of a first infarction. Interpretation of recurrent 
infarction risk is more difficult, particulllrly because multivessel disease 
will adversely influence survival. I accept the fact that measuring Lp( a) 
concentrations to predict infarction risk is unprofitable, but let us not 
discard Lp(a) as a major factor just yet. The real mp-ssage is that studies 
using different end points wiII often give different answers, and 
reconciling these may enhance our understanding of atherosclerosis as 
a whole. 
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Reply 
Establishing cause and effect is a scientific goal that helps to advance 
our understanding of disease and offer insights into the prevention of 
disease. Although an ass')ciation between a potential risk factor and 
disease can support a causal link, it is not sufficient evidence to prove 
cause and effect. As Bradford-Hill summarized several decades ago 
(1), establishing cause and effect requires numerous pieces of evidence 
that include a strong association between the factor and disease, a 
consistent association across several studies, a proper temporal rela. 
tionship (the risk factor occurs before the disease) and a biologically 
plausible mechanism. 
Unlike total cholesterol and low and high density lipoprotein 
cholesterol, lipoprotein{a) [Lp(a)] concentrations satisfy few of these 
requirements as a causal factor for coronary heart disease (CHD). 
Although there is a very plausible biological mechanism [apolipopro-
tein(a) homology to plasminogen and the potential to interfere with 
fibrinolysis], the epidemiologic evidence is notably inconsistent. 
Much of the support for Lp(a) as a CRD risk factor comes frol11 
cross-sectional studies of referred populations, such as those frOI11 
cardiac catheterization laboratories (2-7), lipid clinics (8) or selected 
populations (9). Cross-sectional studies cannot examine the temporal 
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relationship of Lp(a) to CRD, and referred populations that are 
selected by the presence of disease or known risk factors can result in 
biased interpretations. Even the cross-sectional studies of Lp(a) in 
children and disease in adults, such as those referred to by Enas (9,10), 
do not account for the possibility that early manifestations of vascular 
disease, such as endothelial dysfunction, may influence Lp(a) levels in 
children (11). 
The cross-sectional angiographic study of Shaukat et al. (7) found 
a correlation between Lp{a) and an ad-hoc scoring system of extent of 
coronal)' disease (6). However, the substantial correlations between 
Lp(a) and some of the other metabolic variables in their study (7) 
makes the interpretation of their multivariate models difficult. The 
univariate analyses in their study suggested that insulin levels and total 
cholesterol were more strongly related to extent of disease than Lp(a) 
(7). 
There are undoilbtedly genetic differences in apolipoprotein(a) 
frequencies that have a strong influence on the differences in Lp(a) 
between some racial groups. However, cross-sectional studies between 
popUlations or different races within the same population cannot 
determine whether Lp(a) causes CHD, is a consequence of vascular 
disease or is related to CHD indirectly by confounding factors that 
increase both Lp(a) concentrations and CHD risk. 
Enas' concern that patients who died before reaching the hospital 
in our study may have biased our results is not supported by either of 
the studies he cites (12,13). These studies followed up survivors of 
myocardial infarction and would have missed at least as many patients 
who died before enrollment. The first study (12) examined prognosis 
related to blood samples collected 3 months after myocardial infarc-
tion and excluded one-third of the sample from the multivariate 
analysis. The second study (13) found a weak and marginally statisti-
cally significant association with Lp(a) and recurrent myocardial 
infarction on univariate analysis (p = 0.05). On multivariate analysis, 
Lp(a) >30 mg/dl was associated with an odds ratio of 2.16 for further 
acute ischemic events (p = 0.037) (11). 
The prospective population studies, and prospective angiographic 
studies (14), are also divided as to whether Lp{a) was or was not 
associated with CHD. Although some studies found statistically signif-
icant results, the relative risks for the highest levels of Lp(a) are not 
large, with most odds ratios/relative risks <2.0 to 2.5. 
The inconsistency and generally weak magnitude of risk in the 
epidemiologic data cast strong doubts on the case for Lp(a) as a CHD 
risk factor. We propose that Lp(a) could be a marker of vascular or 
tissue damage (14) and that this damage may contribute to serum 
levels, along with the well recognized genetic component. Our hypoth-
esis may be incorrect, but until interventions are demonstrated to be of 
greater value in patients with elevated Lp(a) concentrations, there is 
no clinical justification for measuring Lp(a). 
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